Vertex Pharmaceuticals
在场
是其中之一......
Vertex Pharmaceuticals 是一家在股票代码 VRTX (US) 下上市的公司。
Vertex Pharmaceuticals 在 2 个国家有直接业务。
他们在：
涉及Vertex Pharmaceuticals的并购和融资。
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
- Vertex Pharmaceuticals has announced the acquisition of ViaCyte (公布2022七月13号).
高管
查看带有其 65 名主要高管的组织结构图
Vertex Pharmaceuticals 搜索最多的简介
- Reshma Kewalramani, Director, President and Chief Executive Officer
- Sangeeta Bhatia, Director
- Jeffrey Leiden, Executive Chairman of the Board
高管在Vertex Pharmaceuticals变化
- Nancy Thornberry已作为Director加入公司 (新闻发布的2023十二月6号).
- Michel Lagarde已作为Director加入公司 (新闻发布的2023十月6号).
- Morrey Atkinson 曾任 Senior Vice Presiden and Head of Commercial Manufacturing & Supply Chain, 现升职为 Executive Vice President, Chief Technical Operations Officer and Head of Biopharmaceutical Sciences & Manufacturing Operations (新闻发布的2023八月30号).
创建提醒
跟踪 Vertex Pharmaceuticals 的高管变动
生物技术
Vertex Pharmaceuticals 拥有 2,277 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Histogen has filed for bankruptcy protection (公布2024四月19号).
- Bruker has announced the acquisition of NanoString Technologies (公布2024四月18号).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
生物技术 行业的其他推荐联系人
消息
Vertex Pharmaceuticals 的最新新闻稿
- Press Releases | Vertex Pharmaceuticals Newsroom
- Vertex Advances VX-548 in Acute and Neuropathic Pain | Vertex Pharmaceuticals Newsroom
- Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease | Vertex Pharmaceuticals Newsroom
- Vertex to Announce Second Quarter 2022 Financial Results on August 4 | Vertex Pharmaceuticals Newsroom
- Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
- Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | Vertex Newsroom
- Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference | Vertex Newsroom
- Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 | Vertex Newsroom
- Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA | Vertex Newsroom
- View more press releases Close
通过电子邮件
